ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1650

Malondialdehyde-Acetaldehyde and Citrulline Modified Proteins are Overexpressed in Cardiac Tissues in Rheumatoid Arthritis-Associated Heart Failure and Mediate Endothelial Cell Dysfunction

Hannah Johnson1, Wenxian Zhou2, Michael Duryee1, Engle Sharp1, Kimberley Sinanan1, Carlos Hunter1, Tate Johnson1, Mabruka Alfaidi1, Daniel Anderson3, Geoffrey Thiele1 and Ted Mikuls1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Nebraska Medical Center, Bellevue, NE, 30587964, Durham, NC

Meeting: ACR Convergence 2025

Keywords: autoantigens, Heart disease, Inflammation, macrophages, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: Abstracts: Cytokines & Cell Trafficking (1650–1655)

Session Type: Abstract Session

Session Time: 1:00PM-1:15PM

Background/Purpose: Previous reports show that malondialdehyde-acetaldehyde (MAA) adducts are overexpressed in RA, especially in joint/lung tissues, and that they colocalize with citrulline (CIT). This is relevant as MAA and CIT act synergistically through p38- and NF-κB-dependent pathways to activate macrophages, producing proinflammatory and profibrotic effects mediated through crosstalk with tissue resident cells. Heart failure (HF) is a highly overrepresented cause of death in RA patients, characterized by tissue inflammation, fibrosis, and vascular endothelial dysfunction. Herein, we sought to examine whether MAA has increased expression and colocalization with CIT in heart tissues from patients with RA-HF. We also examined whether inhibition of macrophage signaling pathways limits endothelial cell (EC) activation and inflammation mediated by MAA-CIT stimulation.

Methods: Left ventricular (LV) apex tissue from RA-HF patients and age/sex matched non-RA HF controls were examined (n=3/group). LV tissues were stained with anti-CIT and anti-MAA antibodies. Quantification and co-localization were done using ImageJ and FIJI Coloc2. Separately, human U-937 macrophages were pre-incubated with either media, 1 µM of BIRB-796 (p38 inhibitor), or 50 µM of BAY-11-7085 (NF-κB inhibitor) for 1-hr before stimulation with unmodified fibrinogen (FIB) or FIB co-modified with MAA+CIT (FIB-MAA-CIT) for 48-hrs. To assess the crosstalk between macrophages and ECs, macrophage supernatants were collected and used to indirectly stimulate human coronary artery endothelial cells (HCAECs) for 24-hrs. HCAEC supernatants were then analyzed for IL-6, MCP-1, ICAM-1, and VCAM-1 by ELISA, while RNA was analyzed by RT-PCR. Analyses were performed using a Student’s T test or one-way ANOVA with Tukey’s post hoc test.

Results: LV tissues from RA-HF patients demonstrated trends towards increased CIT deposition (p=0.09) and significantly increased MAA deposition (p< 0.05) vs. non-RA HF controls, with strong co-localization (R2=0.81) (Fig 1). HCAECs stimulated with supernatants from macrophages treated with FIB-MAA-CIT showed significantly increased expression of IL-6, MCP-1, ICAM-1, and VCAM-1 compared to FIB control, validating prior observations. Interestingly, direct stimulation of HCAECs with FIB-MAA-CIT yielded diminished effects (not shown). HCAECs stimulated with supernatants from macrophages pre-treated with p38 or NF-κB inhibitors and FIB-MAA-CIT showed significantly attenuated mRNA expression and soluble cytokine/chemokine production (Figs 2,3).

Conclusion: This study is the first to demonstrate increased MAA expression and MAA-CIT co-localization in cardiac tissues of RA-HF patients compared to non-RA HF patients. We also demonstrated that macrophages activated with FIB-MAA-CIT mediate coronary EC inflammation through their supernatants, an effect that is attenuated following inhibition of p38 and NF-κB. Further research will validate these findings using patient-derived monocytes and explore whether agents targeting MAA, CIT, or downstream signaling pathways have the potential to attenuate cardiac dysfunction that occurs in mouse models of RA.

Supporting image 1Figure 1. Immunohistochemistry Reveals CIT and MAA Expression and Colocalization in the Heart of RA-HF Patients. Representative image of 20X frame at apex of left ventricle is shown. White scale bar = 200 µm. Data shown on graphs are mean ± standard deviation. Student’s T test was performed and the statistical differences between groups are shown in *: * p < 0.05.

Supporting image 2Figure 2. RT-PCR Demonstrating Attenuated HCAEC Inflammatory Gene Expression Following Incubation with Supernatants from Macrophages Stimulated with FIB-MAA-CIT in the Presence or Absence of p38 and NF-κB Inhibitors. 24-hr mRNA expression was measured for; A) IL-6, B) MCP-1, C) ICAM-1, and D) VCAM-1. Relative quotient (RQ) compared to media-cultured negative control cells were calculated and shown in the y-axis. One-way ANOVA was performed and the statistical differences between groups are shown in *: * p < 0.05; *** p < 0.001; **** p < 0.0001.

Supporting image 3Figure 3. ELISA Demonstrating Attenuated HCAEC Inflammatory Protein Release Following Incubation with Supernatants from Macrophages Stimulated with FIB-MAA-CIT in the Presence or Absence of p38 and NF-κB Inhibitors. 24-hr cytokine concentrations in supernatants were measured for; A) IL-6, B) MCP-1, C) ICAM-1, and D) VCAM-1. One-way ANOVA was performed and the statistical differences between inhibitory groups are shown in *: ** p < 0.01; *** p < 0.001; **** p < 0.0001.


Disclosures: H. Johnson: None; W. Zhou: None; M. Duryee: None; E. Sharp: None; K. Sinanan: None; C. Hunter: None; T. Johnson: None; M. Alfaidi: None; D. Anderson: None; G. Thiele: None; T. Mikuls: Amgen, 2, 5, Merck/MSD, 1, Olatech Therapeutics, 1, UCB, 1.

To cite this abstract in AMA style:

Johnson H, Zhou W, Duryee M, Sharp E, Sinanan K, Hunter C, Johnson T, Alfaidi M, Anderson D, Thiele G, Mikuls T. Malondialdehyde-Acetaldehyde and Citrulline Modified Proteins are Overexpressed in Cardiac Tissues in Rheumatoid Arthritis-Associated Heart Failure and Mediate Endothelial Cell Dysfunction [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/malondialdehyde-acetaldehyde-and-citrulline-modified-proteins-are-overexpressed-in-cardiac-tissues-in-rheumatoid-arthritis-associated-heart-failure-and-mediate-endothelial-cell-dysfunction/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/malondialdehyde-acetaldehyde-and-citrulline-modified-proteins-are-overexpressed-in-cardiac-tissues-in-rheumatoid-arthritis-associated-heart-failure-and-mediate-endothelial-cell-dysfunction/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology